Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › CC-486

CC-486

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of CC-486

5 trials tracked of CC-486.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5
  1. Phase 2 Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer Completed
  2. Phase 2 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Completed
  3. Phase 2 Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). Completed
  4. Phase 2 Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma Completed
  5. Phase 2 Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS
Oncology Meta-analysis
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS Different Medications Show Different Benefits for Myelodysplastic Syndromes
This systematic review and network meta-analysis of 20 trials involving 2,877 participants evaluated pharmacological treatments for lower-ri…
New research shows different medications offer varying benefits for patients with lower-risk myelodysplastic syndromes based on specific hea…
Frontiers Jun 17, 2026